The estimated Net Worth of Prabhavathi Fernandes is at least $17.2 Tisíc dollars as of 25 May 2021. Prabhavathi Fernandes owns over 33,500 units of Ocugen Inc stock worth over $17,220 and over the last 5 years he sold OCGN stock worth over $0. In addition, he makes $0 as Independent Director at Ocugen Inc.
Prabhavathi has made over 1 trades of the Ocugen Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 33,500 units of OCGN stock worth $31,155 on 25 May 2021.
The largest trade he's ever made was exercising 33,500 units of Ocugen Inc stock on 25 May 2021 worth over $31,155. On average, Prabhavathi trades about 3,045 units every 0 days since 2020. As of 25 May 2021 he still owns at least 14,000 units of Ocugen Inc stock.
You can see the complete history of Prabhavathi Fernandes stock trades at the bottom of the page.
Dr. Prabhavathi B. Fernandes Ph.D. serves as Independent Director of the Company. Dr. Fernandes has held executive leadership positions at Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. After leaving BMS, she founded and led four biotechnology and CRO companies as President, Chief Executive Officer and Director of each of these companies. Prior to her retirement in December 2016, she led Cempra, Inc. for 12 years as its founder, CEO and chief scientist. Dr. Fernandes currently serves as the Chairperson of both the National Biodefense Science Board (NBSB) and the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership, a Drugs for Neglected Diseases initiative/World Health Organization (DNDi /WHO) initiative. She received her Ph.D. in Microbiology from Thomas Jefferson University. Our Board believes Dr. Fernandes’ extensive experience in the pharmaceutical and biotechnology space provides her with the qualifications and skills to serve on our Board.
Prabhavathi Fernandes is 71, he's been the Independent Director of Ocugen Inc since 2020. There are no older and 16 younger executives at Ocugen Inc.
Prabhavathi's mailing address filed with the SEC is C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355.
Over the last 5 years, insiders at Ocugen Inc have traded over $18,069,176 worth of Ocugen Inc stock and bought 1,511,356 units worth $684,830 . The most active insiders traders include Shankar Musunuri, Junge Zhang a Uday Kompella. On average, Ocugen Inc executives and independent directors trade stock every 21 days with the average trade being worth of $96,347. The most recent stock trade was executed by Junge Zhang on 14 June 2023, trading 200,278 units of OCGN stock currently worth $100,139.
ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
Ocugen Inc executives and other stock owners filed with the SEC include: